Marshall Wace
PROK icon

Marshall Wace’s ProKidney PROK Stock Holding History

Marshall Wace’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,011,744
Closed -$1.81M – 3617
2026
Q1 		$1.81M Buy
1,011,744
+399,259
+65% +$847K ﹤0.01% 1842
2025
Q4 		$1.37M Buy
612,485
+531,279
+654% +$1.4M ﹤0.01% 1776
2025
Q3 		$197K Sell
81,206
-383,606
-83% -$1.02M ﹤0.01% 2576
2025
Q2 		$274K Buy
+464,812
New +$362K ﹤0.01% 2355
2024
Q3 		– Sell
-50,242
Closed -$124K – 2868
2024
Q2 		$124K Buy
+50,242
New +$135K ﹤0.01% 2385
2024
Q1 		– Sell
-23,300
Closed -$41.5K – 2735
2023
Q4 		$41.5K Buy
+23,300
New +$50K ﹤0.01% 2083
2022
Q3 		– Sell
-736,968
Closed -$7.33M – 3702
2022
Q2 		$7.33M Buy
736,968
+548,027
+290% +$5.42M 0.02% 1085
2022
Q1 		$1.86M Buy
188,941
+135,913
+256% +$1.34M ﹤0.01% 2106
2021
Q4 		$524K Hold
53,028
– – ﹤0.01% 2770
2021
Q3 		$520K Buy
53,028
+3,028
+6% +$29.8K ﹤0.01% 2366
2021
Q2 		$507K Buy
+50,000
New +$506K ﹤0.01% 2117

Other funds holding PROK

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $542M AUM 206.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace's PROK Position: Q2 2026 in Review

Marshall Wace sold out of ProKidney (PROK) in Q2 2026, closing a stake of 1,011,744 shares — an estimated $1.81M sold.

Marshall Wace first reported a position in PROK in Q2 2021 and held it in 11 quarters. The position peaked at $7.33M in Q2 2022. 71 funds tracked by Wall St. Rank hold PROK as of Q2 2026.

  • Marshall Wace reported no remaining ProKidney position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 1,011,744 ProKidney shares in Q2 2026, an estimated $1.81M.
  • Marshall Wace first reported a position in ProKidney in Q2 2021 and held it in 11 quarters.
  • Marshall Wace's ProKidney position peaked at $7.33M in Q2 2022.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.